H
Henning Kelbæk
Researcher at University of Copenhagen
Publications - 288
Citations - 15758
Henning Kelbæk is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Myocardial infarction & Percutaneous coronary intervention. The author has an hindex of 52, co-authored 277 publications receiving 14160 citations. Previous affiliations of Henning Kelbæk include Rigshospitalet & Roskilde Sygehus.
Papers
More filters
Journal ArticleDOI
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
Christoph Stettler,Christoph Stettler,Simon Wandel,Sabin Allemann,Adnan Kastrati,Marie Claude Morice,Albert Schömig,Matthias Pfisterer,Gregg W. Stone,Martin B. Leon,José Suárez de Lezo,Jean-Jacques Goy,Seung-Jung Park,Manel Sabaté,Maarten J. Suttorp,Henning Kelbæk,Christian Spaulding,Maurizio Menichelli,Paul Vermeersch,Maurits T. Dirksen,Pavel Cervinka,Anna Sonia Petronio,Alain J Nordmann,Peter Diem,Bernhard Meier,Marcel Zwahlen,Stephan Reichenbach,Sven Trelle,Stephan Windecker,Peter Jüni,Peter Jüni +30 more
TL;DR: A network meta-analysis with a mixed-treatment comparison method to combine direct within-trial comparisons between stents with indirect evidence from other trials while maintaining randomisation found sirolimus-eluting stents seem to be clinically better than bare-metal and paclitaxel-eluted stents.
Journal ArticleDOI
A Comparison of Coronary Angioplasty with Fibrinolytic Therapy in Acute Myocardial Infarction
Henning Rud Andersen,Torsten Toftegaard Nielsen,Klaus Rasmussen,Leif Thuesen,Henning Kelbæk,Per Thayssen,Ulrik Abildgaard,Pedersen F,Jan Madsen,Peer Grande,Anton Boel Villadsen,Lars Romer Krusell,Torben Haghfelt,Preben Lomholt,Steen Husted,Else Vigholt,Henrik K. Kjaergard,Leif Spange Mortensen +17 more
TL;DR: A strategy for reperfusion involving the transfer of patients to an invasive-treatment center for primary angioplasty is superior to on-site fibrinolysis, provided that the transfer takes two hours or less.
Journal ArticleDOI
Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.
Adnan Kastrati,Julinda Mehilli,Jürgen Pache,Christoph Kaiser,Marco Valgimigli,Henning Kelbæk,Maurizio Menichelli,Manel Sabaté,Maarten J. Suttorp,Dietrich Baumgart,Melchior Seyfarth,M Pfisterer,Albert Schömig +12 more
TL;DR: The use of sirolimus-eluting stents does not have a significant effect on overall long-term survival and survival free of myocardial infarction, as compared with bare-metal stents, but there is a sustained reduction in the need for reintervention after the use.
Journal ArticleDOI
Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial
Thomas Engstrøm,Henning Kelbæk,Steffen Helqvist,Dan Eik Høfsten,Lene Kløvgaard,Lene Holmvang,Erik Jørgensen,Frants Pedersen,Kari Saunamäki,Peter Clemmensen,Ole De Backer,Jan Ravkilde,Hans-Henrik Tilsted,Anton Boel Villadsen,Jens Aarøe,Svend Eggert Jensen,Bent Raungaard,Lars Køber +17 more
TL;DR: In patients with STEMI and multivessel disease, complete revascularisation guided by FFR measurements significantly reduces the risk of future events compared with no further invasive intervention after primary PCI, driven by significantly fewer repeat revascularisations.
Journal ArticleDOI
Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events
Lasse Jespersen,Anders Hvelplund,Steen Z. Abildstrom,Frants Pedersen,Søren Galatius,Jan Madsen,Erik Jørgensen,Henning Kelbæk,Eva Prescott +8 more
TL;DR: Patients with stable angina and normal coronary arteries or diffuse non-obstructive CAD have elevated risks of MACE and all-cause mortality compared with a reference population without ischaemic heart disease.